Market Intelligence

Lonza keeps 2019 outlook as specialty ingredients hits rough patch


ZURICH, April 18 () - Swiss drug ingredients maker Lonza stuck to its full-year targets on Thursday and said it would give an update on its business portfolio review in the second half amid "headwinds" in its specialty ingredients division.

The Basel-based company expects mid-to-high-single digit sales growth and a sustained core operating profit margin this year. Without giving specific first-quarter numbers, Lonza said its pharmaceuticals and nutrition unit had "continued positive momentum" while specialty ingredients including anti-microbials for paints and coatings faced unanticipated problems.

"The extent of the challenges across all (specialty ingredients) businesses were not foreseen in January 2019 and the implementation of additional cost-containment measures... has started to mitigate impact of supply-chain disruption and raw material input costs," Lonza said in a statement.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at and via Reuters TV.

Learn More